Related Experiment Video
Updated: Aug 7, 2025

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
Update Breast Cancer 2022 Part 5 - Early Stage Breast Cancer
Tanja N Fehm1, Manfred Welslau2, Volkmar Müller3
1Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany.
Abstract:
The treatment of patients with early stage breast cancer has changed in recent years due to the introduction of pembrolizumab, olaparib, and abemaciclib. These and other drugs with the same class of active ingredient are currently in trial for various indications. This review article summarizes the latest results that have either been presented at major conferences such as the ESMO 2022 or published recently in international journals. This includes reports on newly discovered breast cancer genes, atezolizumab in neoadjuvant therapy in HER2-positive patients, long-term data from the APHINITY study, and on how preoperative peritumoral application of local anesthetics can influence the prognosis. We also present solid data on dynamic Ki-67 from the ADAPT studies.
Insights
Recent advancements in early-stage breast cancer treatment include new drugs like pembrolizumab and updated findings on neoadjuvant atezolizumab and dynamic Ki-67. This review covers key data from ESMO 2022 and recent publications.
Area of Science:
- Oncology
- Medical Research
Background:
- Early-stage breast cancer treatment has evolved with novel therapies.
- Pembrolizumab, olaparib, and abemaciclib represent significant therapeutic advancements.
Purpose of the Study:
- To review recent findings in early-stage breast cancer treatment.
- To summarize key data presented at major conferences and in recent publications.
Main Methods:
- Literature review of recent publications and conference presentations (e.g., ESMO 2022).
- Inclusion of data on novel drug classes, genetic discoveries, and therapeutic approaches.
Main Results:
- Updates on pembrolizumab, olaparib, and abemaciclib in breast cancer.
- New insights into neoadjuvant atezolizumab for HER2-positive patients.
- Long-term data from the APHINITY study and prognostic impact of local anesthetics.
- Presentation of dynamic Ki-67 data from ADAPT studies.
Conclusions:
- The landscape of early-stage breast cancer management is rapidly advancing.
- Emerging data highlight the potential of new drugs and therapeutic strategies.
Related Concept Videos
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

